Neurochemical effects of the monoamine oxidase inhibitor phenelzine on brain GABA and alanine: A comparison with vigabatrin

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 11, Issue 2, 2008, Pages

  Todd, Kathryn G ^a   Baker, Glen B ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ALANINE; GABAERGIC RECEPTOR AFFECTING AGENT; MONOAMINE OXIDASE INHIBITOR; PHENELZINE; VIGABATRIN;

ANIMAL; ARTICLE; BRAIN; COMPARATIVE STUDY; DRUG EFFECT; MALE; METABOLISM; RAT; SPRAGUE DAWLEY RAT;

ALANINE; ANIMALS; BRAIN; GABA AGENTS; GAMMA-AMINOBUTYRIC ACID; MALE; MONOAMINE OXIDASE INHIBITORS; PHENELZINE; RATS; RATS, SPRAGUE-DAWLEY; VIGABATRIN;

EID: 65349095092     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j34s38     Document Type: Article

References (33)

1. Johnson MR, Lydiard RB and Ballenger JC MAOIs in panic disorder and agoraphobia. In Kennedy SH (Ed.), Clinical Advances in Monoamine Oxidase Inhibitor Therapies, American Psychiatric Press Inc., Washington, DC; pp. 205-224, 1994.
2. Gitow F, Lietowitz MR and Schneier FR. MAOI therapy of social phobia. In: Kennedy, S.H. (ed.). Clinical Advances in Monoamine Oxidase Inhibitor Therapies, American Psychiatric Press, Inc., Washington, D.C., pp. 225-254, 1994.
3. Popov N and Matthies H, Some effects of monoamine oxidase inhibitors on the metabolism of γ-aminobutyric acid in rat brain. J Neurochem, 16:899-907, 1969.
4. Baker GB, Wong JT-F, Yeung JM and Coutts RT, Effects of the antidepressant phenelzine on brain levels of γ-aminobutyric acid (GABA). J Affect Dis 21:207-211, 1991.
5. McManus DJ, Baker GB, Martin IL, Greenshaw AJ and McKenna KF, Effects of the antidepressant/antipanic drug phenelzine on GABA concentrations and GABA-transaminase activity in rat brain. Biochem Pharmacol, 43:2486-2489, 1992.
6. Todd KG and Baker GB. GABA-elevating effects of the antipanic/antidepressant drug phenelzine: effects of pre-treatment with tranylcypromine, (-)-deprenyl and clorgyline. J Affec Disord, 35:125-129, 1995
7. Wong JTF, Baker GB, Coutts RT and Dewhurst WG. Long-lasting elevation of alanine in brain produced by the antidepressant phenelzine. Brain Res Bull, 25:179-181, 1990.
8. Tanay VA-MI, Parent MB, Wong JTF, Paslawski T, Martin IL and Baker GB. Effects of the antidepressant/antipanic drug phenelzine on alanine and alanine transaminase in rat brain. Cell Mol. Neurobiol. 2001; 21: 325-339.
9. Wood P, Khan MA, Moskal JR, Todd V, Tanay AMI and Baker GB. Aldehyde load in ischemiareperfusion brain injury: Neuroprotection by neutralization of reactive aldehydes with phenelzine. Brain Res., 1122, 184-190, 2006.
10. Sowa B, Todd KG, Tanay VAM-I, Holt A and Baker GB Monoamine oxidase inhibitors and development of neuroprotective drugs. Current Neuropharmcol., 2: 153-168, 2004.
11. Clineschmidt BV and Horita A, The monoamine oxidase catalyzed degradation of phenelzine-l-14C, an irrerversible inhibitor of monoamine oxidase--I. Studies in vitro. Biochem Pharmacol, 18:1011-1020, 1969
12. Clineschmidt BV and Horita A, The monoamine oxidase catalyzed degradation of phenelzine-l-14C, an irrerversible inhibitor of monoamine oxidase--II. Studies in vivo. Biochem Pharmacol, 18:1021-1029, 1969.
13. Tipton KF and Spires IPC, Oxidation of 2-phenylethylhydrazine by monoamine oxidase. Biochem Pharmacol., 21:268-270, 1972.
14. Patek DR and Hellerman L, Mitochondrial monoamine oxidase. Mechanism of inhibition by phenylhydrazine and by aralkylhydrazines. Role of enzymatic oxidation. J Biol Chem., 249:2373-2380, 1974.
15. Strolin Benedetti M and Dostert P, Contribution of amine oxidases to the metabolism of xenobiotics. Drug Metab Rev., 26:507-535, 1994.
16. Paslawski T, Knaus E, Iqbal N, Coutts RT and Baker GB. β-Phenylethylidenehydrazine, a novel inhibitor of GABA transaminase. Drug Devel. Res, 54:35-39, 2001.
17. Hammond EJ and Wilder BJ Minireview, Gamma-vinyl GABA. Gen Pharmacol, 16:441-447, 1985.
18. Perry TL, Kish SJ, Hansen S, Wright JM, Wall RA, Dunn WL and Bellward GD, Elevation of brain GABA content by chronic low-dosage administration of hydrazine, a metabolite of isoniazid. J Neurochem, 37:32-39, 1981.
19. Bernasconi R, Klein M, Martin P, Christen P, Hafner T, Portet C and Schmutz M, γ-Vinyl GABA: comparison of neurochemical and anticonvulsant effects in mice. J Neural Transm, 72:213-233, 1988.
20. Schecter PJ, Tranier Y and Grove Y, Attempts to correlate alteration in brain GABA metabolism by GABA-T inhibitors with their anticonvulsant effects. Adv Exp Med Biol, 123:43-57, 1979.
21. Sayin Ü, Purali N, Özkan T, Altug T and Büyükdevrim S, Vigabatrin has an anxiolytic effect in the elevated plus-maze test of anxiety. Pharmacol. Biochem. Behav., 43: 529-535, 1992.
22. Paslawski T, Treit D, Baker GB, George M and Coutts RT, The antidepressant drug phenelzine produces antianxiety effects in the plus-maze and increases in rat brain GABA. Psychopharmacology, 127:19-24, 1996
23. Griebel G, Curet O, Perrault G and Sanger DJ, Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs; correlation with changes in monoamine-oxidase activity and monoamine levels. Neuropharmacology, 37: 927-935, 1998.
24. Shuaib A, Ljaz S, Hasan S and Kalra J. Gama-vinyl GABA prevents hippocampal and substantia nigra reticulata damage in repetitive transient forebrain ischemia. Brain Res. 590:13-17, 1992.
25. Zwanzger P and Rupprecht R. Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. J Psychiatry Neurosci., 30(3): 167-175, 2005.
26. Wurtman RJ and Axelrod JA sensitive and specific assay for the estimation of monoamine oxidase. Biochem Pharmacol, 12:1439-1441, 1963.
27. Sterri SH and Fonnum F, Isolation of organic anions by extraction with liquid anion exchangers and its application to micromethods for acetylcholinesterase and 4-aminobutyrate aminotransferase. Eur J Biochem, 91:215-222, 1978.
28. Wong JTF, Baker GB and Coutts RT, A rapid, sensitive assay for γ-aminobutyric acid in brain using electron-capture gas chromatography. Res Commun Chem Path Pharmacol, 70:115-124, 1990.
29. Jung MJ, Lippert B, Metcalf BW, Bohlen P and Schecter PJ, Gamma-vinyl GABA (4-aminohex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: Effects on brain GABA metabolism in mice. J Neurochem, 29:787-802, 1977.
30. Wild JM, Ahn HS, Baulac H, Bursztyn J, Chiron C, Gandolfo E, Safran A, Schiefer U, Peruccs E. Vigabatrin and epilepsy: lessons Learned. Epilepsia, 48(7):1318-1327, 2007.
31. Paul SR, Krauss GL, Miller NR, Medura M, Miller TA and Johnson MA. Visual function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making. Epilepsia, 42(4): 525-530, 2001.
32. Coupland NJ and Nutt DJ, Neurobiology of anxiety and panic. In: Bradwejn J and Vasar E (Eds.), Cholecystokinin and Anxiety: From Neuron to Behavior. Springer, New York, NY. pp1-32, 1995.
33. Dagen SR, Marro KI, Richards TL, Metzger GD, Preliminary application of magnetic resonance spectroscopy to investigate lactate-induced panic. Am. J. Psychiat, 51:57-63, 1994.